{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:01:54Z","timestamp":1780570914631,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01508-9","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:05:01Z","timestamp":1780567501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Sidedness: DNA Methylation as a Biomarker to Refine Anti-EGFR Treatment Selection in RAS\/BRAF Wild-type Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1508_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023;329:1271\u201382.","journal-title":"JAMA"},{"key":"1508_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375.","journal-title":"Lancet Oncol"},{"key":"1508_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713\u201329.","journal-title":"Ann Oncol"},{"key":"1508_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41:678\u2013700.","journal-title":"J Clin Oncol"},{"key":"1508_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040\u20138.","journal-title":"N Engl J Med"},{"key":"1508_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317.","journal-title":"N Engl J Med"},{"key":"1508_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023\u201334.","journal-title":"N Engl J Med"},{"key":"1508_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753\u201362.","journal-title":"Lancet Oncol"},{"key":"1508_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626\u201334.","journal-title":"J Clin Oncol"},{"key":"1508_CR10","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","volume":"96","author":"M Toyota","year":"1999","unstructured":"Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1508_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/ng1834","volume":"38","author":"DJ Weisenberger","year":"2006","unstructured":"Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787\u201393.","journal-title":"Nat Genet"},{"key":"1508_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1101\/gr.117523.110","volume":"22","author":"T Hinoue","year":"2012","unstructured":"Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Van Den Byun HM, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271\u201382.","journal-title":"Genome Res"},{"key":"1508_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/cas.12827","volume":"106","author":"K Ouchi","year":"2015","unstructured":"Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, et al. DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci. 2015;106:1722\u20139.","journal-title":"Cancer Sci"},{"key":"1508_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/cas.15252","volume":"113","author":"K Ouchi","year":"2022","unstructured":"Ouchi K, Takahashi S, Okita A, Sakamoto Y, Muto O, Amagai K, et al. A modified MethyLight assay predicts the clinical outcomes of anti-epidermal growth factor receptor treatment in metastatic colorectal cancer. Cancer Sci. 2022;113:1057\u201368.","journal-title":"Cancer Sci"},{"key":"1508_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00384-022-04177-9","volume":"37","author":"H Osumi","year":"2022","unstructured":"Osumi H, Ouchi K, Shinozaki E, Takahashi S, Ooki A, Nakayama I, et al. Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. Int J Colorectal Dis. 2022;37:1439\u201347.","journal-title":"Int J Colorectal Dis"},{"key":"1508_CR16","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1111\/cas.15367","volume":"113","author":"Y Otsuki","year":"2022","unstructured":"Otsuki Y, Ouchi K, Takahashi S, Sasaki K, Sakamoto Y, Okita A, et al. Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment. Cancer Sci. 2022;113:3221\u201333.","journal-title":"Cancer Sci"},{"key":"1508_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.21037\/jgo-22-862","volume":"14","author":"S Takahashi","year":"2023","unstructured":"Takahashi S, Ouchi K, Sakamoto Y, Mori T, Shimodaira H, Takahashi M, et al. Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. J Gastrointest Oncol. 2023;14:676\u201391.","journal-title":"J Gastrointest Oncol"},{"key":"1508_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00384-024-04659-y","volume":"39","author":"K Ouchi","year":"2024","unstructured":"Ouchi K, Takahashi S, Sasaki K, Yoshida Y, Taniguchi S, Kasahara Y, et al. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: translational research of the EPIC trial. Int J Colorectal Dis. 2024;39:89.","journal-title":"Int J Colorectal Dis"},{"key":"1508_CR19","doi-asserted-by":"publisher","first-page":"105076","DOI":"10.1016\/j.esmoop.2025.105076","volume":"10","author":"K Ouchi","year":"2025","unstructured":"Ouchi K, Sunakawa Y, Tsuji A, Shiozawa M, Kawai T, Yasui H, et al. Genome-wide DNA methylation status as a biomarker for clinical outcomes of first-line treatment in patients with RAS wild-type metastatic colorectal cancer: JACCRO CC-13AR. ESMO Open. 2025;10:105076.","journal-title":"ESMO Open"},{"key":"1508_CR20","doi-asserted-by":"publisher","first-page":"19815","DOI":"10.1038\/s41598-020-76756-1","volume":"10","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Fukuya A, Okamoto K, et al. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Sci Rep. 2020;10:19815.","journal-title":"Sci Rep"},{"key":"1508_CR21","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/bjc.2016.87","volume":"114","author":"MS Lee","year":"2016","unstructured":"Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, et al. Association of CpG island methylator phenotype and EREG\/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114:1352\u201361.","journal-title":"Br J Cancer"},{"key":"1508_CR22","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1200\/JCO.2006.10.5437","volume":"25","author":"S Khambata-Ford","year":"2007","unstructured":"Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230\u20137.","journal-title":"J Clin Oncol"},{"key":"1508_CR23","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1200\/JCO.2008.21.3744","volume":"27","author":"B Jacobs","year":"2009","unstructured":"Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27:5068\u201374.","journal-title":"J Clin Oncol"},{"key":"1508_CR24","doi-asserted-by":"publisher","first-page":"14262","DOI":"10.1038\/ncomms14262","volume":"8","author":"M Schutte","year":"2017","unstructured":"Schutte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017;8:14262.","journal-title":"Nat Commun"},{"key":"1508_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136.","journal-title":"Nature"},{"key":"1508_CR26","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","volume":"21","author":"S Arena","year":"2015","unstructured":"Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res. 2015;21:2157\u201366.","journal-title":"Clin Cancer Res"},{"key":"1508_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Muro K, Watanabe J, Hamaguchi T, Yuki S, Denda T, et al. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024;30:730\u20139.","journal-title":"Nat Med"},{"key":"1508_CR28","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3892\/or.2014.3077","volume":"31","author":"Y Seo","year":"2014","unstructured":"Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, et al. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer. Oncol Rep. 2014;31:2115\u201322.","journal-title":"Oncol Rep"},{"key":"1508_CR29","doi-asserted-by":"publisher","first-page":"1548292","DOI":"10.3389\/fimmu.2025.1548292","volume":"16","author":"R Vincken","year":"2025","unstructured":"Vincken R, Armendariz-Martinez U, Ruiz-Saenz A. ADCC: the rock band led by therapeutic antibodies, tumor and immune cells. Front Immunol. 2025;16:1548292.","journal-title":"Front Immunol"},{"key":"1508_CR30","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/1479-5876-10-232","volume":"10","author":"R Calemma","year":"2012","unstructured":"Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M, et al. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med. 2012;10:232.","journal-title":"J Transl Med"},{"key":"1508_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40291-014-0103-6","volume":"18","author":"Y Inoue","year":"2014","unstructured":"Inoue Y, Hazama S, Suzuki N, Tokumitsu Y, Kanekiyo S, Tomochika S, et al. Fc\u03b3R and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther. 2014;18:541\u20138.","journal-title":"Mol Diagn Ther"},{"key":"1508_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/cells14010032","volume":"14","author":"P Schiele","year":"2025","unstructured":"Schiele P, Kolling S, Rosnev S, Junkuhn C, Walter AL, von Einem JC, et al. Flow cytometric assessment of Fc\u03b3RIIIa-V158F polymorphisms and NK cell mediated ADCC revealed reduced NK cell functionality in colorectal cancer patients. Cells. 2025;14:32.","journal-title":"Cells"},{"key":"1508_CR33","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311\u20139.","journal-title":"J Clin Oncol"},{"key":"1508_CR34","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/cas.16039","volume":"115","author":"H Bando","year":"2024","unstructured":"Bando H, Yamaguchi K, Mitani S, Sawada K, Mishima S, Komine K et al. Japanese Society of Medical Oncology clinical guidelines: molecular testing for colorectal cancer treatment, 5th edition. Cancer Sci. 2024;115:1014-21.","journal-title":"Cancer Sci"},{"key":"1508_CR35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28:1612\u20138.","journal-title":"Nat Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01508-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01508-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01508-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:05:02Z","timestamp":1780567502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01508-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01508-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}